Role of adenosine A2A receptors in motor control: relevance to Parkinson’s disease and dyskinesia

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Journal of neural transmission

• Publication date

  2018-02-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00702-018-1848-6PMID 29396609
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Purinergic Signalling: Therapeutic Developments

  2017cited by this paper
• Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias

  2017cited by this paper
• Non-motor features of Parkinson disease

  2017cited by this paper
• A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L‐DOPA‐induced dyskinesia in Parkinson's disease

  2017cited by this paper
• Purinergic signalling in brain ischemia.

  2016cited by this paper
• Nondopaminergic treatments for Parkinson's disease: current and future prospects.

  2016cited by this paper
• Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease

  2016cited by this paper
• Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms.

  2016cited by this paper
• Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson’s disease: a dose-finding study

  2015cited by this paper
• Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.

  2015cited by this paper
• New insight into the therapeutic role of the serotonergic system in Parkinson's disease.

  2015cited by this paper
• Dual target strategy: combining distinct non‐dopaminergic treatments reduces neuronal cell loss and synergistically modulates l‐DOPA‐induced rotational behavior in a rodent model of Parkinson's disease

  2015cited by this paper
• New treatments for levodopa‐induced motor complications

  2015cited by this paper
• Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease?

  2015cited by this paper
• Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease: Two Randomized Clinical Trials and Lessons Learned.

  2015cited by this paper
• Activation of adenosine A2A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation

  2015cited by this paper
• Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.

  2014cited by this paper
• Advances in non-dopaminergic treatments for Parkinson's disease

  2014cited by this paper
• L-DOPA disrupts adenosine A(2A)-cannabinoid CB(1)-dopamine D(2) receptor heteromer cross-talk in the striatum of hemiparkinsonian rats: biochemical and behavioral studies.

  2014cited by this paper
• An overview of adenosine A2A receptor antagonists in Parkinson's disease.

  2014cited by this paper
• Clinical/pharmacological aspect of adenosine A2A receptor antagonist for dyskinesia.

  2014cited by this paper
• Adenosine A2A Receptor Antagonists in Parkinson’s Disease: Progress in Clinical Trials from the Newly Approved Istradefylline to Drugs in Early Development and Those Already Discontinued

  2014cited by this paper
• Dyskinesia in Parkinson's disease: mechanisms and current non‐pharmacological interventions

  2014cited by this paper
• Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia.

  2014cited by this paper
• Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial.

  2014cited by this paper
• Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations

  2014cited by this paper
• A Critical Evaluation of Behavioral Rodent Models of Motor Impairment Used for Screening of Antiparkinsonian Activity: The Case of Adenosine A2A Receptor Antagonists

  2014cited by this paper
• Study of the antidyskinetic effect of eltoprazine in animal models of levodopa‐induced dyskinesia

  2013cited by this paper
• Introduction to purinergic signalling in the brain.

  2013cited by this paper
• A2A receptor antagonists do not induce dyskinesias in drug-naive or L-dopa sensitized rats.

  2013cited by this paper
• Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.

  2013cited by this paper
• Long‐term safety and efficacy of preladenant in subjects with fluctuating Parkinson's disease

  2013cited by this paper
• Istradefylline: First Global Approval

  2013cited by this paper
• GPCR heteromers and their allosteric receptor-receptor interactions.

  2012cited by this paper
• The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease

  2012cited by this paper
• A2A Receptor Antagonism and Dyskinesia in Parkinson's Disease

  2012cited by this paper
• Potential therapeutic relevance of adenosine A2B and A2A receptors in the central nervous system.

  2012cited by this paper
• Adenosine A2A receptor in the monkey basal ganglia: Ultrastructural localization and colocalization with the metabotropic glutamate receptor 5 in the striatum

  2012cited by this paper
• Presynaptic control of serotonin on striatal dopamine function

  2011cited by this paper
• Arousal Effect of Caffeine Depends on Adenosine A2A Receptors in the Shell of the Nucleus Accumbens

  2011cited by this paper
• Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia.

  2011cited by this paper
• Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

  2011cited by this paper
• Pharmacological and Physiological Characterization of the Tremulous Jaw Movement Model of Parkinsonian Tremor: Potential Insights into the Pathophysiology of Tremor

  2011cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• The serotonergic system in Parkinson's disease.

  2011cited by this paper
• International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

  2011cited by this paper
• Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial.

  2011cited by this paper
• Preladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disorders.

  2010cited by this paper
• Adenosine signaling and function in glial cells

  2010cited by this paper
• A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.

  2010cited by this paper
• Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants

  2010cited by this paper
• THEMED ISSUE: CANNABINOIDS REVIEW Adenosine–cannabinoid receptor interactions. Implications for striatal functionbph_723 443..453

  2010cited by this paper
• Characterization of the Potent and Highly Selective A2A Receptor Antagonists Preladenant and SCH 412348 [7-[2-[4-2,4-Difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in Rodent Models of Movement Disorders and Depression

  2009cited by this paper
• Adenosine receptors and the central nervous system.

  2009cited by this paper
• The scientific and clinical basis for the treatment of Parkinson disease (2009)

  2009cited by this paper
• Detection of heteromerization of more than two proteins by sequential BRET-FRET

  2008cited by this paper
• Blockade of globus pallidus adenosine A2A receptors displays antiparkinsonian activity in 6‐hydroxydopamine‐lesioned rats treated with D1 or D2 dopamine receptor agonists

  2008cited by this paper
• Detection of Heteromers Formed by Cannabinoid CB1, Dopamine D2, and Adenosine A2A G-Protein-Coupled Receptors by Combining Bimolecular Fluorescence Complementation and Bioluminescence Energy Transfer

  2008cited by this paper
• The effects of adenosine A2A receptor antagonists on haloperidol-induced movement disorders in primates

  2008cited by this paper
• Tremorolytic effects of adenosine A2A antagonists: implications for parkinsonism.

  2008cited by this paper
• Adenosine A2A receptor antagonist istradefylline (KW‐6002) reduces “off” time in Parkinson's disease: A double‐blind, randomized, multicenter clinical trial (6002‐US‐005)

  2008cited by this paper
• Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors.

  2008cited by this paper
• Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.

  2008cited by this paper
• Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

  2008cited by this paper
• Molecular mechanisms of L-DOPA-induced dyskinesia

  2008cited by this paper
• A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease

  2008cited by this paper
• The A3 adenosine receptor: an enigmatic player in cell biology.

  2008cited by this paper
• Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.

  2007cited by this paper
• Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats.

  2007cited by this paper
• Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.

  2007cited by this paper
• Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6‐hydroxydopamine rat model of Parkinson's disease

  2007cited by this paper
• Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial

  2007cited by this paper
• Fluorescence studies of homooligomerization of adenosine A2A and serotonin 5-HT1A receptors reveal the specificity of receptor interactions in the plasma membrane.

  2007cited by this paper
• Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.

  2007cited by this paper
• Striatal Adenosine A2A and Cannabinoid CB1 Receptors Form Functional Heteromeric Complexes that Mediate the Motor Effects of Cannabinoids

  2007cited by this paper
• Targeting adenosine A2A receptors in Parkinson's disease.

  2006cited by this paper
• Post‐ versus presynaptic plasticity in L‐DOPA‐induced dyskinesia

  2006cited by this paper
• The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.

  2006cited by this paper
• Presynaptic Control of Striatal Glutamatergic Neurotransmission by Adenosine A1–A2A Receptor Heteromers

  2006cited by this paper
• Forebrain Adenosine A2A Receptors Contribute to l-3,4-Dihydroxyphenylalanine-Induced Dyskinesia in Hemiparkinsonian Mice

  2006cited by this paper
• Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists.

  2006cited by this paper
• Reversion of levodopa‐induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6‐OHDA‐lesioned rats

  2006cited by this paper
• Behavioral models of Parkinson's disease in rodents: A new look at an old problem

  2006cited by this paper
• Different synaptic and subsynaptic localization of adenosine A2A receptors in the hippocampus and striatum of the rat.

  2005cited by this paper
• Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.

  2005cited by this paper
• Co‐localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum

  2005cited by this paper
• Astrocytic Purinergic Signaling Coordinates Synaptic Networks

  2005cited by this paper
• Adenosine and brain function.

  2005cited by this paper
• Interactions between Metabotropic Glutamate 5 and Adenosine A2A Receptors in Normal and Parkinsonian Mice

  2005cited by this paper
• Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.

  2005cited by this paper
• Dopamine and adenosine receptor interaetion as basis for the treatment of Parkinson's disease

  2005cited by this paper
• New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists.

  2005cited by this paper
• Effects of sarizotan on the corticostriatal glutamate pathways

  2005cited by this paper
• Motor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations

  2005cited by this paper
• Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions.

  2004cited by this paper
• The origin of motor fluctuations in Parkinson’s disease

  2004cited by this paper
• Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.

  2004cited by this paper
• Multicenter, Open-Label, Trial of Sarizotan in Parkinson Disease Patients With Levodopa-Induced Dyskinesias (the SPLENDID Study)

  2004cited by this paper
• Staging of brain pathology related to sporadic Parkinson's disease.

  2003cited by this paper
• Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD

  2003cited by this paper

• NMDA receptor remodeling and nNOS activation in mice after unilateral striatal injury with 6-OHDA

  2024cites this paper
• Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

  2024cites this paper
• The interaction of adenosine and dopamine in modulating the consequences of central nervous system oxygen toxicity.

  2024cites this paper
• Purple Carrot Extract Exhibits A Neuroprotective Profile In The Nigrostriatal Pathway In The Reserpine-Induced Model Of Parkinson's Disease.

  2024cites this paper
• Molecular and Structural Insight into Adenosine A2A Receptor in Neurodegenerative Disorders: A Significant Target for Efficient Treatment Approach

  2023cites this paper
• Mouse and rat ultrasonic vocalizations in neuroscience and neuropharmacology: State of the art and future applications

  2023cites this paper
• Promising biomarkers and therapeutic targets for the management of Parkinson's disease: recent advancements and contemporary research

  2023cites this paper
• Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study

  2022cites this paper
• A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?

  2022cites this paper
• Adenosine A2A Receptor Occupancy by Caffeine After Coffee Intake in Parkinson's Disease

  2022cites this paper
• Chalcones as Potential Ligands for the Treatment of Parkinson’s Disease

  2022cites this paper
• Transcriptome Profiling Reveals Differential Expression of Circadian Behavior Genes in Peripheral Blood of Monozygotic Twins Discordant for Parkinson’s Disease

  2022cites this paper
• P2X7 Receptor and Purinergic Signaling: Orchestrating Mitochondrial Dysfunction in Neurodegenerative Diseases

  2022cites this paper
• Caffeine improves mitochondrial function in PINK1B9-null mutant Drosophila melanogaster

  2022cites this paper
• Addressing the Neuroprotective Actions of Coffee in Parkinson’s Disease: An Emerging Nutrigenomic Analysis

  2022cites this paper
• Protective Agents in Parkinson’s Disease: Caffeine and Adenosine A2A Receptor Antagonists

  2021cites this paper
• Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson's Disease.

  2021cites this paper
• The Implication of STEP in Synaptic Plasticity and Cognitive Impairments in Alzheimer’s Disease and Other Neurological Disorders

  2021cites this paper
• New Insights into Pathogenesis of L-DOPA-Induced Dyskinesia.

  2021cites this paper
• Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists

  2021cites this paper
• Blockade of adenosine A2A receptors inhibits Tremulous Jaw Movements as well as expression of zif-268 and GAD65 mRNAs in brain motor structures.

  2021cites this paper
• The role of neuroimaging in Parkinson’s disease

  2021cites this paper
• Research Progress in Pathophysiological Mechanism of Dyskinesia in Parkinson's Disease

  2021cites this paper
• Adenosine receptor antagonists: Recent advances and therapeutic perspective.

  2021cites this paper
• Novel Therapeutic Interventions for Combating Parkinson's Disease and Prospects of Nose-to-Brain Drug Delivery.

  2021cites this paper
• Progress in Pathophysiological Mechanism of Dyskinesia in Parkinson ’ s Disease

  2021cites this paper
• Pharmacological interactions between adenosine A2A receptor antagonists and different neurotransmitter systems.

  2020cites this paper
• Pharmacology of Adenosine Receptors

  2020cites this paper
• The activity of the Striatal‐enriched protein tyrosine phosphatase in neuronal cells is modulated by adenosine A2A receptor

  2020cites this paper
• Effects of CATECHIN on reserpine-induced vacuous chewing movements: behavioral and biochemical analysis

  2020cites this paper
• Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications

  2020cites this paper
• Purinergic Signalling in Parkinson’s Disease: A Multi-target System to Combat Neurodegeneration

  2019cites this paper
• Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease

  2019cites this paper
• Adenosine and Adenosine A2A Receptors as Targets for the Treatment of Niemann Pick Type C Disease

  2019cites this paper
• Research progress on adenosine in central nervous system diseases

  2019cites this paper
• Adenosine A2A receptor as potential therapeutic target in neuropsychiatric disorders.

  2019cites this paper
• Occupancy of adenosine A2A receptors by istradefylline in patients with Parkinson's disease using 11C‐preladenant PET

  2018cites this paper